How to Buy Ocular Therapeutix Stock
Ocular Therapeutix Inc
Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
Ocular Therapeutix stock last closed at $7.61, up 4.1% from the previous day, and has increased 49.95% in one year. It has overperformed other stocks in the Biotechnology industry by 1.28 percentage points. Ocular Therapeutix stock is currently +87.44% from its 52-week low of $4.06, and -35.37% from its 52-week high of $11.78.
As of Apr 21, 2025, there are 159.02M shares of OCUL outstanding. The market value of OCUL is $1.21B. In the past 24 hours, 975,567 OCUL shares were traded.
How to Buy Ocular Therapeutix Stock
Wondering how to invest in Ocular Therapeutix stock? Here's how.
- Choose where to buy Ocular Therapeutix stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you determine where to buy Ocular Therapeutix stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Put funds into your brokerage account: Pick your payment method and add your info.
- Analyze Ocular Therapeutix stock: The Ocular Therapeutix ticker symbol is OCUL. Is Ocular Therapeutix stock a good investment? Should you buy shares of OCUL? How do OCUL's underlying business fundamentals look? Do top analysts think Ocular Therapeutix is a good buy? Why has OCUL's stock price moved recently? (Hint: Our stock analysis website can help you figure out if OCUL is a good stock to buy).
- Execute your OCUL trade: Decide if you will purchase OCUL shares at the current market price or use a limit order to purchase OCUL stock at a particular price.
- Watch your investment in OCUL: Create a watchlist to get live updates on your investment in Ocular Therapeutix shares.
Step 1: Choose where to buy Ocular Therapeutix stock
You need a brokerage account in order to access the NASDAQ market and buy OCUL shares.
Our recommended brokerage: eToro
In our opinion, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal information so you are able to buy OCUL today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open your new brokerage account.
- Send your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have filled out your info on the greatest app to buy stocks, you need to deposit funds:
Check out the video below to see the process of transferring money into your investment account.
Step 4: Analyze Ocular Therapeutix stock
After you have chosen the best place to buy Ocular Therapeutix stock, it's very important to analyze their stock prior to investing, so you can wrap your head around the risk as well as the upside.
Ocular Therapeutix shares at a glance
Ocular Therapeutix Fundamentals
WallStreetZen was designed to help average investors perform more accurate fundamental analysis quickly.
You can view all of the due diligence checks on OCUL's stock page.
Is OCUL stock undervalued?
Investors use many financial metrics, analyses, models, and charts to gauge OCUL's true value.
Using relative valuations ratios:
- OCUL could be undervalued based on its P/B ratio of 3.84x, relative to Biotechnology industry P/B ratio of 4.04x
You can access additional valuation analysis on OCUL's stock here.
OCUL Financial Summary
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the OCUL balance sheet.
- Total OCUL debt is lower than 5 years ago, relative to shareholder equity.
- OCUL has cash burn of 135965000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the OCUL balance sheet.
- OCUL has $393.72M in cash and short term investments. This is enough to cover its annual cash burn of $135.97M.
Negative Health Checks:
- OCUL has a relatively high debt to equity ratio of 0.45.
- OCUL profit margin has gone down from -138.1% to -303.7% in the past year.
Do analysts think it's a good time to buy Ocular Therapeutix stock
Out of 4 Wall Street analysts who give forecasts on OCUL, the consensus analyst rating on OCUL is a Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are projecting on the Ocular Therapeutix stock forecast page.
OCUL Momentum
Is OCUL Growing Revenue?
Last year, OCUL revenue was $63.72M. In the past 5 year, OCUL's revenue has grown by 72.05% per year. This was faster than the Biotechnology industry average of 44.31%.
Dig into OCUL's earnings and revenue performance here.
What are OCUL executives and large shareholders up to?
Over the last year, executives and large shareholders at OCUL have sold more shares than they have bought.
Pravin Dugel, Executive Chairman President and CEO of OCUL, was the latest OCUL insider to sell. They sold $147,533.25 worth of OCUL stock on Feb 24, 2025.
Dig into more about who owns OCUL shares here.
Does OCUL provide a stable income stream?
No, Ocular Therapeutix doesn't provide an income stream by paying out dividends.
What others are saying about OCUL
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your OCUL trade
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at an exact price limit, place a limit order.
Click the Open button and your broker will execute your order.
If you require additional assistance buying stocks on eToro, watch the helpful video below:
Step 6: Watch your investment in OCUL
Now that you own some OCUL stock, you'll want to stay up-to-date on your investment.
Make a watchlist to get alerted to the latest events about your OCUL stock.
OCUL Feed
How to Buy Stock in Ocular Therapeutix
To summarize, here are the 6 steps to buy Ocular Therapeutix stock:
- Choose where to buy Ocular Therapeutix stock
- Create a brokerage account
- Put funds into your brokerage account
- Analyze Ocular Therapeutix stock
- Execute your OCUL trade
- Watch your investment in OCUL
If you are looking for a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to monitor your investment in Ocular Therapeutix, add OCUL to your watchlist by clicking the button below.
Other "How To" Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.